A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7--19+ weeks' duration. The usual time to the occurrence of a greater than 25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
hodgkin's disease
12
phase study
8
stage ivb
8
ivb hodgkin's
8
study cis-dischlorodiammineplatinumii
4
cis-dischlorodiammineplatinumii stage
4
disease broad
4
broad phase
4
study cis-dichlorodiammineplatinumii
4
cis-dichlorodiammineplatinumii conducted
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!